论文部分内容阅读
目的:研究紫杉醇纳米粒腹腔给药对大鼠卵巢癌的治疗效果,初步探讨其作用机制。方法:用超声乳化法制备紫杉醇纳米粒;用MTT法测定紫杉醇纳米粒对NU-TU19细胞增殖的抑制率;荷瘤鼠腹腔给药,比较其荷瘤量及腹水量;用HE染色研究肿瘤浸润;(5)流式细胞仪研究肿瘤细胞周期分布与凋亡。结果:(1)紫杉醇纳米粒粒径200nm,包封率70%;(2)紫杉醇纳米粒及市售紫杉醇IC50分别为98.50±1.55ng/m l,97.95±1.48ng/m l,差异无统计学意义(P>0.05);(3)紫杉醇纳米粒治疗组动物荷瘤量及腹水量分别为4.56±0.11g,3.55±0.50m l,市售紫杉醇为10.13±0.52g,30.45±1.55m l,差异有统计学意义(P<0.01);(4)HE染色结果显示,纳米粒组肿瘤细胞核分裂相少见,且不侵犯淋巴结;(5)纳米粒组肿瘤细胞凋亡率为(36.51±0.42)%,市售紫杉醇组为(20.63±0.11)%,差异有统计学意义(P<0.01)。结论:低剂量紫杉醇纳米粒腹腔给药安全,治疗卵巢癌有较好效果。
OBJECTIVE: To study the therapeutic effect of paclitaxel nanoparticles intraperitoneally on rat ovarian cancer and to explore its mechanism. Methods: The paclitaxel nanoparticles were prepared by phacoemulsification. The inhibition rate of paclitaxel nanoparticles on the proliferation of NU-TU19 cells was determined by MTT assay. The tumor-bearing mice and the ascites volume were compared. The tumor infiltration ; (5) Flow Cytometry to study tumor cell cycle distribution and apoptosis. Results: (1) paclitaxel nanoparticles with a diameter of 200nm and encapsulation efficiency of 70%; (2) IC50 of paclitaxel nanoparticles and paclitaxel were 98.50 ± 1.55ng / ml and 97.95 ± 1.48ng / ml, respectively, with no significant difference (P> 0.05). (3) The tumor volume and the amount of ascites in the paclitaxel-treated group were 4.56 ± 0.11g and 3.55 ± 0.50ml respectively, and the average paclitaxel was 10.13 ± 0.52g and 30.45 ± 1.55ml (4) The results of HE staining showed that the mitotic phase of the tumor cells in the nanoparticle group was rare and did not infiltrate the lymph nodes. (5) The apoptosis rate of the tumor cells in the nanoparticle group was (36.51 ± 0.42)%, Paclitaxel group was (20.63 ± 0.11)%, the difference was statistically significant (P <0.01). Conclusion: Paclitaxel nanoparticles can be safely administered intraperitoneally to treat ovarian cancer.